Astellas Jump-Starts Ophthalmology Ambitions With Ocata Buy
This article was originally published in PharmAsia News
Executive Summary
Astellas's planned $379m purchase of US regenerative medicine venture Ocata will give the Japanese firm a new presence in ophthalmology and strengthen its cell therapy capabilities.
You may also be interested in...
Astellas Targets ALS In Expansion Of Cytokinetics Alliance
Astellas and Cytokinetics are expanding their existing alliance to investigate two candidates against amyotrophic lateral sclerosis, as the Japanese firm looks to build its strategic interests in muscle disease.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.